Drugs / ML-004
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05889273 | Jun 2023 → Nov 2027 expected | autism spectrum disorder | MapLight Therapeutics | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05081245 | Sep 2022 → Mar 2026 | autism spectrum disorder | MapLight Therapeutics | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-22 | MapLight Therapeutics | Results MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder maplightrx.com ↗
The IRIS Phase 2 trial did not meet its primary endpoint in social communication deficits associated with ASD |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-22 | MapLight Therapeutics | MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder maplightrx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ML-004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05889273 ↗ |
| Route | Oral | “ML-004 is taken orally once daily.” NCT05081245 ↗ |